ArticleThe Journal of international medical research2026
Risk stratification in colorectal cancer: A retrospective cohort study of nomograms based on inflammatory and immunohematological biomarkers.
Article in The Journal of international medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveInflammation and immunohematological biomarkers are recognized as contributing factors in the progression of solid tumors. This study aimed to develop nomograms incorporating inflammatory and immunohematological biomarkers to predict the prognosis of colorectal cancer.MethodsWe retrospectively enrolled 432 patients with colorectal cancer at Yunnan Cancer Hospital from January 2019 to December 2022. Clinicopathologic data and blood samples were obtained at initial diagnosis before any treatment, and therapy was initiated within 3 days. Patients with prior therapy, secondary cancers, or systemic conditions affecting hematology were excluded. Metastases were confirmed by pathology or imaging, and overall survival and progression-free survival were recorded through follow-up. Multivariate logistic and Cox regression analyses, nomogram construction, and internal validation with 1000-bootstrap resampling were performed using R, with risk groups defined by receiver operating characteristic curve-derived cutoffs.ResultsIn the training cohort, the model accuracy for predicting distant metastasis was 66.25%. The concordance index values for the three nomograms were 0.791 (95% confidence interval, 0.745-0.838), 0.752 (95% confidence interval, 0.699-0.806), and 0.687 (95% confidence interval, 0.647-0.726), respectively. Calibration plots showed strong agreement between predicted and observed outcomes, while decision curve analysis indicated potential clinical utility. Subgroup analyses confirmed that the nomograms were effective prognostic indicators across stage I-IV colorectal cancer patients (P < 0.05).ConclusionSingle or combined hematological indicators are readily obtainable and feasible and possess high prognostic value. Nomograms based on cancer-associated inflammatory factors and immunohematological biomarkers demonstrated robust accuracy in predicting distant metastasis, overall survival, and progression-free survival in patients with colorectal cancer. These tools may assist clinicians in risk stratification and treatment decision-making, ultimately supporting improved oncological outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.